Patent 11485743 was granted and assigned to Kymera Therapeutics on November, 2022 by the United States Patent and Trademark Office.
The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.